Apogee TherapeuticsAPGE
About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
Employees: 91
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]
54% more capital invested
Capital invested by funds: $2.14B [Q2] → $3.29B (+$1.15B) [Q3]
3.69% more ownership
Funds ownership: 120.94% [Q2] → 124.63% (+3.69%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 46
1% less funds holding
Funds holding: 139 [Q2] → 138 (-1) [Q3]
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
83% less call options, than puts
Call options by funds: $2.65M | Put options by funds: $15.2M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wedbush David Nierengarten 42% 1-year accuracy 27 / 64 met price target | 84%upside $87 | Outperform Reiterated | 25 Oct 2024 |
